A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence and nature of dose-limiting toxicities (DLTs)
Length of study
Rainer Brachmann, M.D.
United States: Food and Drug Administration